WaldencastWALD
WALD logo
Fair Value
US$2.28
Share price29 Jun
US$1.7324.0% undervalued intrinsic discount
Loading
1Y1.76%
7D2.37%

Expansion Into Ulta Beauty Stores Will Boost Future Success

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
30 Mar 25
Updated
29 Jun 26
Views
53
Not Invested

Last Update 29 Jun 26

Fair value Increased 22%

WALD: Obagi Sale And Injectables Expansion Will Support Future Share Rebound

The analyst price target for Waldencast has been raised from $1.87 to $2.28, with analysts pointing to the announced sale of the Obagi skin care and aesthetics business for up to $460 million as a key factor supporting the higher valuation.

What’s in the News for Waldencast

  • Waldencast announced that the U.S. Food and Drug Administration approved Obagi saypha ChIQ injectable hyaluronic acid gel, expanding the Obagi Medical injectable portfolio and targeting cheek augmentation and midface contour correction for patients over 21.
  • Obagi Medical shared new clinical and real world data at the Music City SCALE meeting in Nashville, including a 12 week study on NU-GEN Cellular Renewal Serum and interim results from the ALOHA Program evaluating Obagi saypha MagIQ dermal filler alongside medical grade skincare.
  • Obagi Medical partnered with Next Health on “The Skin Recharge Station,” a limited time pop up truck in Southern California that promotes NU-GEN Cellular Renewal Serum, offers Aura skin analyses, and provides access to NAD+ focused wellness experiences.
  • Waldencast disclosed that the U.S. Securities and Exchange Commission staff concluded its investigation into the company’s historical accounting practices related to Obagi Cosmeceuticals and does not intend to recommend an enforcement action, following Waldencast’s voluntary contact and cooperation.
  • Waldencast reported that Chief Executive Officer Michel Brousset entered into a reinvestment agreement tied to the Obagi transaction and plans to depart at closing. Board chair Felipe Dutra is expected to serve as interim CEO during the transition.

Valuation Changes for Waldencast

  • Fair Value: The updated analyst fair value estimate has risen from $1.87 to $2.28 per share, an increase of around 22%.
  • Discount Rate: The discount rate has fallen from 10.34% to 9.35%, indicating a lower required return being applied in the valuation work.
  • Revenue Growth: The assumed revenue growth rate has risen from 6.08% to 7.49%, reflecting higher expected top line expansion for Waldencast in the model.
  • Net Profit Margin: The assumed net profit margin has increased slightly from 6.19% to 6.24%, implying a modest shift in expected profitability levels.
  • Future P/E: The future P/E assumption has moved up from 16.85x to 19.04x, indicating a higher valuation multiple being used for Waldencast's forward earnings.
1 viewusers have viewed this narrative update

Key Takeaways

  • Strong growth in Milk Makeup and Obagi Medical, with store expansion and innovation driving increased future revenue and market share.
  • Operational efficiencies and improved cash flow enhance financial flexibility, allowing for further sales and marketing investments, boosting top-line growth.
  • Regulatory investigation, macroeconomic factors, and strategic execution risks challenge Waldencast's liquidity, revenue growth, and profitability, requiring careful management and optimization of strategic initiatives.

Catalysts

About Waldencast
    Operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand.
What are the underlying business or industry changes driving this perspective?
  • Strong growth in both Milk Makeup and Obagi Medical brands, with Milk Makeup expanding into Ulta Beauty stores, leading to expected mid-teens revenue growth. This channel expansion is likely to drive increased future revenue.
  • Operational efficiencies and sturdy gross margins facilitated by the Waldencast flywheel effect are expected to provide room for further investments in sales and marketing, aiding top-line momentum, thus impacting future net margins positively.
  • Successful execution of innovation strategies, including new product launches in both the skincare and makeup segments, are likely to boost future revenue and market share.
  • Securing a new $205 million, 5-year credit facility extends debt maturity and enhances financial flexibility, potentially improving future earnings by reducing financial risks.
  • Expected improvements in cash generation following the resolution of nonrecurring regulatory expenses will enable stronger cash flow, which could be utilized for growth investments or debt reduction.
Waldencast Earnings and Revenue Growth

Waldencast Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Waldencast's revenue will grow by 7.5% annually over the next 3 years.
  • Analysts are not forecasting that Waldencast will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Waldencast's profit margin will increase from -84.4% to the average US Personal Products industry of 6.2% in 3 years.
  • If Waldencast's profit margin were to converge on the industry average, you could expect earnings to reach $21.1 million (and earnings per share of $0.16) by about June 2029, up from -$229.7 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.1x on those 2029 earnings, up from -0.8x today. This future PE is greater than the current PE for the US Personal Products industry at 17.3x.
  • Analysts expect the number of shares outstanding to grow by 4.59% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 9.35%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Waldencast's ongoing regulatory investigation has resulted in significant cash usage for nonrecurring expenses, potentially limiting liquidity and impacting net earnings until the matter is resolved.
  • The macroeconomic environment and retail inventory adjustments have led to slowed market growth and could affect revenue growth, especially as competitive and consumer market conditions may change unpredictably.
  • The aggressive expansion into Ulta may cannibalize existing sales from Sephora, leading to dilution of revenue per outlet and potentially reducing overall profitability if not managed carefully.
  • There is execution risk associated with Milk Makeup's strategic plans, especially as they expand into the complexion category and seek to maintain strong brand equity through new innovation, potentially affecting profit margins if the innovations don't meet market expectations.
  • Significant reliance on growth strategies such as marketing investments and international expansion requires careful management of operational costs and investment returns, which, if not optimized, could lead to stagnation in EBITDA margin improvement and overall net profit growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $2.27 for Waldencast based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.0, and the most bearish reporting a price target of just $1.6.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $337.9 million, earnings will come to $21.1 million, and it would be trading on a PE ratio of 19.1x, assuming you use a discount rate of 9.3%.
  • Given the current share price of $1.46, the analyst price target of $2.27 is 35.8% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Waldencast?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$2.28
vs US$1.7324.0% undervalued intrinsic discount
PastFuture-202m338m202020222024202620282029Revenue US$337.9mEarnings US$21.1m
7.5%
Revenue growth
6.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Waldencast

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Adequate balance sheet and slightly overvalued.

Market capUS$219.3m
PB0.4x
Estimated Growth7.3%
Dividend YieldN/A
Full analysis

CEO & management

Michel Brousset
CEO
2.4yrs
CEO Tenure

Operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand.